Manikandanesan Sakthivel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manikandanesan Sakthivel has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Mogan Kaviprawin
Ganga Medical Centre and Hospital
2 shared publications - Polani Rubeshkumar
ICMR – National Institute of Epidemiology , Chennai, Tamil Nadu , India
2 shared publications - Prabhdeep Kaur
Indian Institute of Science (IISc), Bangalore, India
2 shared publications - Salin K Eliyas2 shared publications
- Yuvaraj Krishnamoorthy
Department of Community Medicine, ESIC Medical College & PGIMSR, K.K. Nagar, Chennai, India
2 shared publications Abhishek Kunwar
Division of Noncommunicable Diseases, WHO Country Office for India
1 shared publication
Latest Publications
- 21 September 2026
- Published by The R Foundation
gtstats: Beginner-Friendly Statistics and Publication-Ready Tables
Provides beginner-friendly functions for common descriptive and inferential statistical analyses, together with tools for creating publication-ready tables. The package includes data description, summary statistics, distribution assessment, group comparisons, effect sizes, correlations, proportions and rates with confidence intervals, crosstabs for epidemiological measures, plots, and modular table-building workflows. Statistical methods include unequal-variance comparisons described by Welch (1947) , score confidence intervals described by Wilson (1927) , and robust variance assessment described by Brown and Forsythe (1974) .
- 21 September 2026
- Published by The R Foundation
gtstats: Beginner-Friendly Statistics and Publication-Ready Tables
Provides beginner-friendly functions for common descriptive and inferential statistical analyses, together with tools for creating publication-ready tables. The package includes data description, summary statistics, distribution assessment, group comparisons, effect sizes, correlations, proportions and rates with confidence intervals, crosstabs for epidemiological measures, plots, and modular table-building workflows. Statistical methods include unequal-variance comparisons described by Welch (1947) , score confidence intervals described by Wilson (1927) , and robust variance assessment described by Brown and Forsythe (1974) .
- 18 August 2025
- Published by The R Foundation
gtregression: Tools for Creating Publication-Ready Regression Tables
Simplifies regression modeling in R by integrating multiple modeling and summarization tools into a cohesive, user-friendly interface. Designed to be accessible for researchers, particularly those in Low- and Middle-Income Countries (LMIC). Built upon widely accepted statistical methods, including logistic regression (Hosmer et al. 2013, ISBN:9781118548429), log-binomial regression (Spiegelman and Hertzmark 2005 ), Poisson and robust Poisson regression (Zou 2004 ), negative binomial regression (Hilbe 2011, ISBN:9780521179515), and linear regression (Kutner et al. 2005, ISBN:9780071122214). Leverages multiple dependencies to ensure high-quality output and generate reproducible, publication-ready tables in alignment with best practices in epidemiology and applied statistics.
- 18 August 2025
- Published by The R Foundation
gtregression: Tools for Creating Publication-Ready Regression Tables
Simplifies regression modeling in R by integrating multiple modeling and summarization tools into a cohesive, user-friendly interface. Designed to be accessible for researchers, particularly those in Low- and Middle-Income Countries (LMIC). Built upon widely accepted statistical methods, including logistic regression (Hosmer et al. 2013, ISBN:9781118548429), log-binomial regression (Spiegelman and Hertzmark 2005 ), Poisson and robust Poisson regression (Zou 2004 ), negative binomial regression (Hilbe 2011, ISBN:9780521179515), and linear regression (Kutner et al. 2005, ISBN:9780071122214). Leverages multiple dependencies to ensure high-quality output and generate reproducible, publication-ready tables in alignment with best practices in epidemiology and applied statistics.
- Open Access
- 16 July 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-12
Socioeconomic and sex disparities in hypertension and diabetes mellitus care cascade among tribal populations in Odisha, India: findings from the Odisha Tribal Family Health Survey (OTFHS), 2022–23
We assessed sex and socioeconomic disparities in the care cascade, i.e., awareness, treatment, and control (ATC), for hypertension and diabetes among Odisha’s tribal communities. We surveyed 14 tribal districts via multistage cluster sampling covering 10,090 households from 2022 to 23. Data from individuals aged > 18 years were analyzed for hypertension (BP > 140/90 mmHg) and diabetes (RBS > 200 mg/dL). The outcomes included (i) awareness (prior diagnosis or medication use), (ii) treatment (self-reported medication use), and (iii) control (BP < 140/90 mmHg for hypertension, RBS < 180 mg/dL for diabetes). Multivariable log-binomial regression was used to estimate adjusted prevalence ratios (aPRs with 95% CIs) for gender and wealth quintile associations with ATC stages. Of the 21,100 participants, 33.7% had hypertension and 9.7% had diabetes. Among the 6,620 hypertensive individuals, 19% were aware, 13·8% were on treatment, and 6·8% had controlled BP. Women with hypertension (N = 3,609) had significantly better outcomes than men did: awareness (aPR: 1·4;1·2–1·6), treatment (aPR: 1·5; 1·2–1·7), and control (aPR: 1·7; 1·4–2·2). Compared with those in the poorest quintile, hypertensive individuals from the richest quintile (N = 1,804) were more likely to be aware (aPR: 1·5; 1·2-1·9) and on treatment (aPR: 1·5; 1·2–2·7); however, BP control was not significantly different (aPR: 1·6; 0·9-2·8). Among the 1,883 individuals with diabetes, 49% were aware, 44·4% were on treatment, and 40·7% achieved control. Significant socioeconomic and sex inequities persist in hypertension care among Odisha’s tribal populations, with better ATC outcomes for women and wealthier individuals. Targeted screening and gender-sensitive approaches are essential for equitable healthcare access.
- 16 July 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-12
Open AccessSocioeconomic and sex disparities in hypertension and diabetes mellitus care cascade among tribal populations in Odisha, India: findings from the Odisha Tribal Family Health Survey (OTFHS), 2022–23
We assessed sex and socioeconomic disparities in the care cascade, i.e., awareness, treatment, and control (ATC), for hypertension and diabetes among Odisha’s tribal communities. We surveyed 14 tribal districts via multistage cluster sampling covering 10,090 households from 2022 to 23. Data from individuals aged > 18 years were analyzed for hypertension (BP > 140/90 mmHg) and diabetes (RBS > 200 mg/dL). The outcomes included (i) awareness (prior diagnosis or medication use), (ii) treatment (self-reported medication use), and (iii) control (BP < 140/90 mmHg for hypertension, RBS < 180 mg/dL for diabetes). Multivariable log-binomial regression was used to estimate adjusted prevalence ratios (aPRs with 95% CIs) for gender and wealth quintile associations with ATC stages. Of the 21,100 participants, 33.7% had hypertension and 9.7% had diabetes. Among the 6,620 hypertensive individuals, 19% were aware, 13·8% were on treatment, and 6·8% had controlled BP. Women with hypertension (N = 3,609) had significantly better outcomes than men did: awareness (aPR: 1·4;1·2–1·6), treatment (aPR: 1·5; 1·2–1·7), and control (aPR: 1·7; 1·4–2·2). Compared with those in the poorest quintile, hypertensive individuals from the richest quintile (N = 1,804) were more likely to be aware (aPR: 1·5; 1·2-1·9) and on treatment (aPR: 1·5; 1·2–2·7); however, BP control was not significantly different (aPR: 1·6; 0·9-2·8). Among the 1,883 individuals with diabetes, 49% were aware, 44·4% were on treatment, and 40·7% achieved control. Significant socioeconomic and sex inequities persist in hypertension care among Odisha’s tribal populations, with better ATC outcomes for women and wealthier individuals. Targeted screening and gender-sensitive approaches are essential for equitable healthcare access.
- Open Access
India Hypertension Control Initiative- Blood Pressure Control using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022
Background Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre-and post-treatment. Results Of 281,209 patients initiated on Amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with Amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76% to 81%) increase was seen in the second step after adding Telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.
Open AccessIndia Hypertension Control Initiative- Blood Pressure Control using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022
Background Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre-and post-treatment. Results Of 281,209 patients initiated on Amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with Amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76% to 81%) increase was seen in the second step after adding Telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.
- Open Access
Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
Open AccessEffectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.